Article Data

  • Views 1507
  • Dowloads 150


Open Access

Treatment with erythropoietin in neonatology


1Clinical department of Paediatrics, Maribor University Medical Centre, Maribor, Slovenia

2Clinical department of Gynaecology and Perinatology, Maribor University Medical Centre,Maribor, Slovenia

DOI: 10.22514/SV112.062016.13 Vol.11,Issue S2,June 2016 pp.61-65

Published: 14 June 2016

*Corresponding Author(s): MIKSIĆ MIRJANA E-mail:


The article presents the basics and con-trol of erythropoiesis in the fetus and the newborn, the development of anaemia of prematurity and its treatment, with an em-phasis on the use of human recombinant erythropoietin. The Intensive Care Unit of the Paediatric Clinic Maribor began treat-ing anaemia of prematurity with eryth-ropoietin in 2000. After introducing the treatment, the clinic found that the num-ber of blood product transfusions and the needed blood volume decreased. In addi-tion to erythropoietin, this was the result of stricter criteria for applying transfusion of concentrated erythrocytes.


preterm infant, anaemia of pre-maturity, erythropoietin, transfusion

Cite and Share

MIKSIĆ MIRJANA,DUKIĆ VUKOVIĆ TANJA,POGOREVC ROBERT,TREIBER MILENA. Treatment with erythropoietin in neonatology. Signa Vitae. 2016. 11(S2);61-65.


1. Stockman IA III, DeAlarcon PA. Hematopoiesis and Granulopoiesis. In: Polin RA, Fox WW, editors. Fetal and Neonatal Physiology, Philadelphia: WB Saunders; 1992. p. 1327-1363.

2. Heikinheimo M, Siimes MA. Regulation of erythropoiesis in the newborn: A complex system. Ann Med. 1992;24;309 -311.

3. Dessypris EN, Krantz SB. Erythropoietin; Regulation of erythropoiesis and clinical use. Adv Pharmacol. 1990;21:127-147.

4. Attias D. Pathophysiology and treatment of the anemia of prematurity. J Pediatr Hematol Oncol. 1995;17:13-18.

5. Boissel JP, Bunn HF. Erythropoietin structure-function relationships. Prog Clin Biol res. 1990;352:227-232.

6. Choi D, Kim M, Park J. Erythropoietin: Physico-and biochemical analysis. J Chromatogr B. 1996;687:189-199.

7. Lacombe C, Da Silva JL, Bruneval P, Casadevall N, Camilleri JP, Bariety J, et al. Erythropoietin: Sites of synthesis and regulation of secretion. Am J Kidney Dis. 1991;18(Suppl I): 14-19.

8. Juul SE, Yachnis AT, Christensen RD. Tissue distribution of erythropoietin and erythropoietin receptor in the developing human fetus. Early Hum Devel. 1998;52:235-249.

9. Roth P. Anemia in preterm infants. Pediatr Rev. 1996;17:370.

10. Curtis JA. Physiologic anemia. Pediatr Rev. 1995;16:356-366.

11. Ohls RK, Harcum J, Schibler KR, Christensen RD. The effect of erythropoietin on the transfusion requirements of preterm infants weighing 750 grams or less; A randomized, double-blind, placebo-controlled study. J Pediatr. 1997;131:661-665.

12. Strauss RG. Red blood cell transfusions in the neonate. Clin Perinatol. 1995;22:641-655.

13. Halperin DS, Felix M, Wacker P, Lacourt G, Babel JF, Wyss M. The anemia of prematurity. Causes and therapeutic consequences. In: Bauer C, Koch KM, Scigalla P, Wieczorek L, editors. Erythropoietin: Molecular physiology and clinical applications. New York: Marcel Dekker Inc; 1993. p. 365-377.

14. Ohis RK. The use of erythropoietin in neonates. Clin Perinatol. 2000;27:681-698.

15. Dintinjana M. Tveganje za prenos okužbe s krvjo in krvnimi pripravki [Risk of infection transfer with blood and blood products]. In: Bregant L, editor. Nebakterijske okužbe v perinatologiji [Non-bacterial infections in perinatology]. Ljubljana: Združenje za peri-natalno medicino SZD; 1998. p. 119-124.

16. Hudson I, Cooke A, Holland A, Jones JG, Turner T, Wardrop CAJ. Red cell volume and cardiac output in anaemic preterm infants. Arch Dis Child. 1990;65:672-675.

17. Halperin DS. Risk of neonatal transfusion and potential use of recombinant human erythropoietin. Curr Opin Pediatr. 1990;2:289-303.

18. EPOMAX. Mišljenje Zavoda za farmakologiju Medicinskog fakulteta Sveučilišta u Zagrebu o stavljanju lijeka u promet [Notice of the Pharmacology Institute of the Medical Faculty of the University of Zagreb on marketing authorizations for medicinal products]. Zagreb: Zavod za farmakologiju; 1994.

19. Erslev AJ. Erythropoietin. N Engl J Med. 1991;324:1339-1344.

20. Bratanič B, Paro Panjan D. Anemija nedonošenčkov [Anemia of preterm infants]. In: Kržišnik C, Brecelj Anderluh M, editors. Pedi-atrija [Pediatrics]. Ljubljana: DZS; 2013. p. 216-217.

21. Cazzola M. How and when to use erythropoietin. Curr Opin Hematol. 1998;5:103-8.

22. Pincus T, Olsen NJ, Russell IJ, Wolfe F, Harris R, Schwitzer T, et al. Multicenter study of recombinant human erythropoietin in cor-rection of anemia in rheumatoid arthritis. Am J Med. 1990;89:161-168.

23. Davis HP, Brown H. Erythropoietin alpha for anaemia of chronic leukemia. Lancet. 1991;337:347.

24. Sherwood JB, Goldwasser E, Chilcote R. Sickle cell anemia patients have low erythropoietin levels for their degree of anemia. Blood. 1986;67:46-49.

25. Henry DH, Spivak JL. Clinical use of erythropoietin. Curr Opin Hematol. 1995;2:118-124.

26. Vora M, Gruslin A. Erythropoietin in obstetrics. Obstet Gynecol Surv. 1998;53:500-508.

27. Brown MS, Jones MA, OHLS RK, Christensen RD. Single dose pharmacokinetics of recombinant human erythropoietin in preterm infants after intravenosus and subcutaneous administartion. J Pediatr. 1993;122:655-657.

28. Halperin DS, Wacker P, Lacourt G, Felix M, Babel JF, Aapro M, et al. Effects of recombinant human erythropoietin in infants with anemia of prematurity. Eur J Pediatr. 1990;116:779-786.

29. Beck D, masserey E, Meyer M, Calame A. Weekly intravenous administration of recombinant human erythropoietin in infants with anemia of premturity. Eur J Pediatr. 1991;150:767-772.

30. Carnielli V, Montini G, Da Riol R, Dall Armico R, Cantarrutti F. Effects of high doses of human recombinant erythropoietin on the need for blood tranfusions in preterm infants. J Pediatr. 1992;121:98-102.

31. Maier RF, Obladen M, Scigalla P, Linderkamp O, Duc G, Hieronimi G et al. The effect of epoetin beta (recombinant human erythro-poietin) on the need for transfusion in very-low-birth-weight infants. NEJM. 1994;330:1173-1178.

32. Shannon K, Keith JF, Mentzer W, Ehrenkranz RA, Brown MS, Widness JA, et al. Recombinant human erythropoietin stimulates erythropoiesis and reduces erythrocyte transfusions in very low birth weight preterm infants. Pediatrics. 1995;95:1-8.

33. Konhauser Cerar L. Liječenje anemije zbog nedonošenosti rekombinantnim humanim eritropoetinom [Treating anemia of prema-turity with recombinant human erythropoietin. MA [thesis]. Zagreb: University of Zagreb; 2000.

34. Cristensen RD, Levvit S, Calhoun DA. Non-hematopoietic actions of hematopoietic growth factors. Bio neonate. 2002;82:298-299.

35. Ohis RK, Wirkus PE, Christensen RD. Recombinant erythropoietin as treatment for the late hyporegenerative anemia of Rh hemo-lytic disease. Pediatrics. 1992;90:678-680.

36. Bifano EM, Curran TR. Minimising donor blood exposure in the neonatal intensive care unit. Current trends and future prospects. Clin Perinatol. 1995;22:657-669.

37. Wetskamp E, Soditt V, Adrian S, Bohnhorst B, Groneck P, Poets CF. Blood transfusion in anemic infants with apnea of prematurity. Biol Neonate. 2002;82:228-232.

38. Shireman T, Hilsenrath PE, Strauss RG, Wiciness JA; Mutnick AH. Recombinant human erythropoietin vs tranfusions in the tret-ment of the anemia of prematurity: a cost-benefit analysis. Arch Pediatr Adolesc Med. 1994;148:582-588.

39. Fain J, Hilsenrath P, Widness JA, Strauss RG, Mutnick AH. A cost analysis comparing erythropoietin and red cell transfusions in the treatment of anemia of prematurity. Transfusion. 1995;36:936-943.

40. Dame C, Juul SE, Christensen RD. The biology of erythropoietin in the central nervous system and its neurotrophic and neuroprotec-tive potential. Bio Neonate 2001;79:228-235.

41. Aher SM, Ohlsson A. Late erythropoietin for preventing red blood cell transfusion in preterm and/or low birth weight infants. Cochrane Database Syst Rev. 2014 Apr 23;4.

42. Ohls RK, Christensen RD, Kamath-Rayne BD, et al. A randomized, masked, placebo controlled study of darbepoetin alfa in preterm infants. Pediatrics. 2013;132(1):119-127.

43. Patel S, Ohls R. Darbepoetin Administration in Term and Preterm Neonates. Clin Perinatol. 2015;42:557-566.

Abstracted / indexed in

Science Citation Index Expanded (SciSearch) Created as SCI in 1964, Science Citation Index Expanded now indexes over 9,200 of the world’s most impactful journals across 178 scientific disciplines. More than 53 million records and 1.18 billion cited references date back from 1900 to present.

Journal Citation Reports/Science Edition Journal Citation Reports/Science Edition aims to evaluate a journal’s value from multiple perspectives including the journal impact factor, descriptive data about a journal’s open access content as well as contributing authors, and provide readers a transparent and publisher-neutral data & statistics information about the journal.

Chemical Abstracts Service Source Index The CAS Source Index (CASSI) Search Tool is an online resource that can quickly identify or confirm journal titles and abbreviations for publications indexed by CAS since 1907, including serial and non-serial scientific and technical publications.

Index Copernicus The Index Copernicus International (ICI) Journals database’s is an international indexation database of scientific journals. It covered international scientific journals which divided into general information, contents of individual issues, detailed bibliography (references) sections for every publication, as well as full texts of publications in the form of attached files (optional). For now, there are more than 58,000 scientific journals registered at ICI.

Geneva Foundation for Medical Education and Research The Geneva Foundation for Medical Education and Research (GFMER) is a non-profit organization established in 2002 and it works in close collaboration with the World Health Organization (WHO). The overall objectives of the Foundation are to promote and develop health education and research programs.

Scopus: CiteScore 1.0 (2022) Scopus is Elsevier's abstract and citation database launched in 2004. Scopus covers nearly 36,377 titles (22,794 active titles and 13,583 Inactive titles) from approximately 11,678 publishers, of which 34,346 are peer-reviewed journals in top-level subject fields: life sciences, social sciences, physical sciences and health sciences.

Embase Embase (often styled EMBASE for Excerpta Medica dataBASE), produced by Elsevier, is a biomedical and pharmacological database of published literature designed to support information managers and pharmacovigilance in complying with the regulatory requirements of a licensed drug.

Submission Turnaround Time